tbuckley/cabot-search huggingface dataset:
Public Reporting of Percutaneous Coronary Intervention Outcomes
Authors: Rishi K. Wadhera, Colin W. O’Brien, Karen E. Joynt Maddox, Kalon K.L. Ho, Duane S. Pinto, Frederic S. Resnic, Pinak B. Shah, Robert W. Yeh
Journal: Journal of the American College of Cardiology (2019)
In geriatric evaluation, some iadl (Katz) scale items are more predictive of efficacy and toxicity than ADL (Lawton) scale or Charlson Comorbidity Index in metastasic castration-resistant protate cancer (mCRPC) patients treated with cabazitaxel in a weekly schedule.
Authors: Miguel Angel Climent Duran, Begoña Pérez-Valderrama, Begona Mellado, Eva Fernandez Parra, Ovidio Fernandez Calvo, Urbano Anido Herranz, Montserrat Domenech, Susana Hernando Polo, Jose Angel Arranz, Cristina Caballero Diaz, María José Juan Fita, Daniel E. Castellano, Maria ochoa De Olza
Journal: Journal of Clinical Oncology (2019)

176 Background: Cabazitaxel (CBZ) improves overall survival in mCRPC that progresses during or after docetaxel treatment. CABASEM is a phase II study to evaluate the efficacy and safety of a weekly schedule of CBZ for 'unfit' (ECOG2, previous neutropenic fever with docetaxel, or radiotherapy to &lt;25% of areas of bone marrow reserve) mCRPC patients after docetaxel failure. Fragility scales were performed to patients included before treatment and results are described. Methods: All 70 patients were treated with CBZ 10 mg/m2/wk 4 administration every 5 weeks. Geriatric fragility scales performed were Lawton daily day activities (ADL), BPI score, Katz instrumental daily day activities (IADL) and Charlson index. General and specific items have been analyzed in relation with toxicity and efficacy (clinical benefit (OR+SD), PSA response, composite PFS, PSA-PFS, and overall survival) in all patients and in older than 70 years. Results: Median age 73 (range 54-85). Charlson index and ADL scale had not relationship with any toxicity observed and any efficacy outcome in the whole group nor in older than 70. IADL independence grade was related to survival in the whole group (p=0,025) and older than 70 (p=0,02). In the whole group, some IADL items were associated with PSA response (buying, p=0.003; cooking, p=0.06; and IADL independence grade p=0.01), PSA PFS (telephone use, p=0.01; handle finances, p=0.06), composite PFS (telephone use, p=0.013; housekeeping, p=0.03; handle finances, p=0,06) and OS (telephone use p=0.001; laundry, p=0.008; handle finances, p=0.02 and IADL dependence grade, p=0.003). Only any grade diarrhea and grade 2 neutropenia was associate with buying (p=0.025) and cooking (p=0.05) IADL items respectively, in patients older than 70 years. Conclusions: IADL scale and items seem to be more related to efficacy (OS, PSA response, PFS, clinical benefit and PSA PFS) than ADL and Charlson scales in mCRPC older than 70 years treated with weekly cabazitaxel. No clear association of scales and items with toxicity were observed in this group of patients. Clinical trial information: NCT01518283.
Midterm Reproducibility of Chest Magnetic Resonance Imaging in Adults with Clinically Stable Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Authors: Mark O. Wielpütz, Monika Eichinger, Sabine Wege, Ralf Eberhardt, Marcus A. Mall, Hans-Ulrich Kauczor, Michael U. Puderbach, Frank Risse, Claus P. Heußel, Gudula Heußel
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
Comparison of Clinical Characteristics and Prognosis of a Series of Patients from the Spanish Registry of MDS Diagnosed with Myelodysplastic/Myeloproliferative Neoplasms According to the 2016 Reviewed Classification of the World Health Organization
Authors: Blanca Xicoy, María-José Jimenez, Olga García, Marisa Calabuig, Rosa Coll, Elisa Orna, María Teresa Cedena, Ana Vicente, Eugenia Rivero, Itziar Oiartzabal Ormategui, Lurdes Zamora, Jose-Angel Hernandez, Natalia Estrada, Marta Callejas, Bernardo Javier González González, Raquel de Paz, Montserrat Cortes, Laura Palomo, Joan Bargay, María-Lavinia Villalobos, Alicia Bailen, María-Ángeles Montañés, Teresa Bernal Del Castillo, Félix López Cadenas, Javier Grau, Salut Brunet, Ana Jiménez, Guillermo Sanz, Josefa Marco, Tzu Hua Chen-Liang
Journal: Blood (2018)
Are we done with the immunohistochemical classification of hepatocellular adenoma? [1618]
Authors: Anne Aurelie Raymond, Brigitte Le Bail, Valerie Paradis, Linda Ferrell, Amedeo Sciarra, Matthew M. Yeh, Andrew D. Clouston, Gregory Miller, Christine Sempoux, Alberto Quaglia, Annette S. Gouw, Swan N. Thung, Juan Putra, Jean-Frederic Blanc, Frederic Saltel, Charles Balabaud, Paulette Bioulac-Sage
Journal: Hepatology (2017)
Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design
Authors: Joanne Sowter, Dimitrios A Koutoukidis, Maggie Heinrich, Orla McCourt, Allan Hackshaw, Rebecca Beeken, Dunnya De-Silva, Stephanie Philpott, Ali Rismani, Neil K Rabin, Rakesh Popat, Charalampia Kyriakou, Atul Mehta, Bruce Paton, Abigail Fisher, Kwee Yong
Journal: Blood (2018)
Prognostic significance of day+14 plasma cell count after initial induction therapy in Acute Myeloid Leukemia.
Authors: Abhishek Avinash Mangaonkar, Rohini Chintalapally, Ashis Mondal, Ravindra B. Kolhe, Vamsi Kota
Journal: Journal of Clinical Oncology (2015)

e18056 Background: Induction therapy regimens for acute myeloid leukemia (AML) target attainment of complete remission. Bone marrow biopsy is done usually after two to three weeks after the start of therapy to assess response, indicated by clearance of leukemic blast cells. Some patients are noted to have an increased bone marrow plasma cell count in the residual marrow. We aimed to study if this elevated plasma cell count has any prognostic signficance. Methods: A retrospective chart review was conducted on 81 AML patients from 2005 to 2014 after obtaining institutional review board approval. Patients treated with 7 and 3 (cytarabine/anthracycline) induction regimen after initial diagnosis were included. Untreated or patients treated with other chemotherapeutic regimens such as hypomethylating agents, patients undergoing subsequent induction regimens were excluded from the study. Bone marrow plasma cell (noted as day+14 plasma cell count) and absolute lymphocyte count from bone marrow done between days 14 and 21 after the start of initial induction therapy was recorded, along with other patient characteristics such as age, sex, French-American-British (FAB) classification, cytogenetics/molecular studies, infections ≤ 6 months before, during and ≤ 6 after initial induction therapy and whether patients received an allogeneic stem cell transplant or not. Results: Mean day+14 plasma cell count and residual leukemic blast cell percentage (%) were 9.93 & 17.29 respectively. There was no significant correlation between day+14 % plasma cell count and overall survival (r = 0.114, p = 0.180). Also, Day+14 % plasma cell count did not show a significant positive correlation with residual leukemic blasts (r = -0.18, p = 0.076). Infections during and ≤ 6 months after induction therapy did not affect day 14 plasma cell count. Residual % lymphocyte count did not show a significant correlation with day+14 % plasma cell count. Conclusions: Based on the results, we could not find any prognostic significance for day+14 plasma cell count in AML patients undergoing their first induction cycle with 7 and 3 regimen as it did not correlate with either residual leukemic blast cell percentage or overall survival.
Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting
Authors: A. Broeker, M. Nardecchia, K.P. Klinker, H. Derendorf, R.O. Day, D.J. Marriott, J.E. Carland, S.L. Stocker, S.G. Wicha
Journal: Clinical Microbiology and Infection (2019)
Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose-dense MVAC.
Authors: Yongjune Lee, Young Seok Kim, Bumsik Hong, Yong Mee Cho, Jae-Lyun Lee
Journal: Journal of Clinical Oncology (2019)

376 Background: Prospective randomized trials demonstrated efficacy of MVAC (Methotrexate, Vinblastine, Doxorubicin, Cisplatin) neoadjuvant chemotherapy (NAC) in muscle invasive bladder cancer (MIBC). In metastatic setting urothelial cell carcinoma (UCC), clinical trials showed no difference in oncologic outcomes between Gemcitabine-Cisplatin (GC) and MVAC, and another prospective trial proved dose-dense (dd) MVAC had significantly better overall survival (OS) and response rate then MVAC. Comparative data between GC and ddMVAC are limited in neoadjuvant setting. Methods: A retrospective analysis of patients with urothelial carcinoma (cT2-4aN0-1M0) who received NAC from January 2011 and December 2017 in Asan Medical Center was conducted. Patients who received GC were compared to patients received ddMVAC in terms of outcomes including downstaging ( &lt; ypT2 and no N upstaging), pathologic complete response (pCR, ypT0N0), disease-free survival (DFS), and overall survival (OS) and tolerability. Results: In a total of 277 patients, 176 patients received NAC with GC and 41 patients with dose-dense MVAC. The median chemotherapy cycle is 4 (IQR 3-4) cycles for GC group, 4 (IQR 3-5.5) cycles for dose-dense MVAC group. With an exception of age; GC group is associated with younger age (p = 0.002), other baseline characteristics are well balanced between groups. Downstaging rate are 50.8% in GC group, 58.1% in dose-dense MVAC group (p = 0.47). The rates of achieving ypT0 (28.7% vs 22.6%, p = 0.68), ypN0 (78.3% vs 81.5%, p = 0.39). There were no differences in overall survival (OS) at 3 year (72.2% vs 73.2%, p = 0.58), disease-free survival (DFS) at 3 years (54.9% vs 63.3%, p = 0.21) according to chemotherapy regimens. ddMVAC with prophylactic G-CSF are associated with higher incidence of febrile neutropenia (p = 0.004) than GC. NAC regimen is not independent prognostic factor for OS on multivariable analysis. Conclusions: GC regimen had no significant difference in oncologic outcomes compare to ddMVAC as NAC in UCC.
Abstract P280: The Association of Sleep Apnea with Psychiatric History: A Veteran Twin Study
Authors: Minxuan Huang, Donald L Bliwise, Amit J Shah, Jack H Goldberg, Yi-An Ko, Nancy Murrah, Oleksiy M Levantsevych, Lucy H Shallenberger, J. Douglas Bremner, Viola Vaccarino
Journal: Circulation (2019)

Introduction: Sleep apnea is exceedingly common in elderly men and is associated with higher risk of cardiovascular disease. Post-traumatic stress disorder (PTSD) and depression have been shown to be associated with sleep apnea, however results have not been consistent, and it is unclear whether this association is confounded by cardiovascular and behavioral risk factors. In this study, our objective was to explore the risk factors for sleep apnea with a focus on psychiatric history, and we hypothesized that the association of sleep apnea with psychiatric history can be largely influenced by cardiovascular and behavioral factors. Methods: This was a cross-sectional analysis of 100 members of the Vietnam Era Twin (VET) Registry (50 twin pairs, mean age=68; range: 61-71 years). All twins underwent a one night in-lab polysomnography (PSG) to assess the apnea/hypopnea index (AHI). Clinical diagnoses of lifetime history of major depression and PTSD were obtained with the Structured Clinical Interview for DSM V (SCID); we also measured current depressive symptoms with the Beck Depression Inventory-II (BDI-II). To assess associations of study variables with AHI, within-pair differences in multivariable mixed-effects regression models were examined and β coefficients were calculated. In addition to lifetime history of depression and PTSD, we included in the model the following variables previously reported in the literature to be associated with AHI: body mass index (BMI), current smoking, history of alcohol abuse, and physical activity assessed with the Baecke score. Other variables included years of education, sedative/hypnotic use, and antidepressant use. Results: The mean AHI among these men was 15.5 [SD=16.1]. A total of 18 and 28 twins had diagnoses of lifetime history of depression and PTSD, respectively. In bivariate analysis without adjustment for covariates, psychiatric history (depression or PTSD) was not significantly associated with higher AHI. In mixed-effects multivariable regression analysis, only higher BMI (β=2.3, 95% CI=1.5, 3.1) and less education (β=-1.3, 95% CI=-2.4, -0.1) were independently associated with higher AHI. Psychiatric history of depression (β=3.9, 95% CI=-3.5, 11.3) or PTSD (β=6.0, 95% CI=-0.9, 12.9) were not significantly associated with AHI. Additional analyses examining number of depressive symptoms (BDI-II) showed similar results. Conclusion: As expected, higher BMI was associated with higher AHI, but several other variables thought to be associated with higher AHI were not confirmed, such as smoking status, alcohol abuse, sedative/hypnotic use, and lack of physical activity. In contrast to the prevailing literature, neither lifetime history of depression nor PTSD were associated with sleep apnea. However, the role for poor sleep quality other than sleep-disordered breathing still remains to be investigated.
Barriers and facilitators to digital health collaboration between academia and industry: a cross-cultural analysis
Authors: Chelsea Liu, Shuai Shao, Janet Prvu Bettger, Chang Liu, Lijing Yan
Journal: The Lancet Global Health (2019)

BackgroundIn a landscape of rising chronic disease burden in middle-income and high-income countries, digital health is seen as a promising solution to improving population health. Importantly, the development and uptake of digital health technologies require multisectoral efforts from academia and industry. However, few have explored the factors that help or hinder the success of these collaborations. Our study aims to identify the themes, barriers, and facilitators associated with industry–academia collaborations in digital health in middle-income and high-income countries.MethodsTrained researchers conducted semi-structured interviews with 23 stakeholders who are active in industry (n=11), academia (n=11), or both (n=1) using prespecified interview guides. Stakeholders were based in World-Bank-defined middle-income countries (China, India; n=15) or high-income countries (USA, Australia, Singapore; n=8). Interviews were conducted in the stakeholder's language of choice (Chinese, n=12; English, n=11). Qualitative interview questions elicited discussions about stakeholders' past experience with academia–industry collaboration, challenges they faced, and factors that facilitated the process. Interviews were audiotaped, transcribed verbatim, and analysed using inductive content analysis. A codebook was developed by the research team over five iterations and used by two bilingual coders to thematically code the data.FindingsFour central themes emerged from the discussions: stakeholder role in collaboration, communication between partners, goals or expectations, and individual priorities. Stakeholders in both academia and industry identified several facilitating factors for successful collaborations: the adoption of complementary roles; authentic communication between partners; and clearly outlined goals or expectations before the collaboration begins. Misaligned goals or expectations, particularly differences in timeline and difficulties balancing business outcomes versus scientific evidence, were identified as the primary barriers. Stakeholders in high-income countries reported inauthentic communication as a significant barrier to collaboration, whereas those in middle-income countries did not.InterpretationThis study highlights the need for increased planning and communication prior to and throughout collaborations between academia and industry in the field of digital health. Outlining each party's goals and expectations about timelines, assigning complementary roles, and communication about priorities will facilitate fruitful collaborations in the future. Furthermore, best practices for communication styles may depend on the cultural setting and, thus, should be adopted accordingly.FundingNone.
Prolonged, low dose infusion versus standard dose rate infusion of gemcitabine: A meta-analysis.
Authors: Bo Li, Yihe Yang
Journal: Journal of Clinical Oncology (2015)

e13570 Background: Gemcitabine is considered as one of the most active chemotherapies for many malignancies. However, efficacy of the current standard infusion regimen was not satisfying and toxicity limited its usage. A meta-analysis was undertaken to assess the value of prolonged, low-dose infusion of gemcitabine. Methods: We searched Medline, Pubmed and Embase for studies published between 2000 and 2015 that compared efficacy and safety of prolonged, low-dose vs. standard dose rate infusion of gemcitabine on any type of malignancies. 4 randomized controlled trails, which included 309 advanced stage of non-small cell lung cancer (NSCLC, stage IIIB/IV)(1, 2), 106 non-metastatic NSCLC(3) and 120 advanced bladder cancer (stage III/IV)(4), met our search criteria and were assessed. 268 received prolonged, low-dose infusion, defined as 250-350mg/m2 in prolonged 6-hours infusion. 267 received standard dose rate infusion, defined as 1000-1250mg/m2in a standard 20-30 minutes infusion. Efficacy evaluated included overall response rate (OR), complete response rate (CR) and partial response rate (PR). Toxicity evaluated included severe anemia, neutropenia, thrombocytopenia and nausea/vomiting, defined as stage 3/4 in Common Toxicity Criteria of the National Cancer Institute v2.0 or grade 3/4 in Common Terminology Criteria for Adverse Events, v3.0. Random-effect meta-analytical model was performed. Results: Overall response rate was significantly higher in the prolonged, low dose infusion group compared to the standard dose rate infusion group (OR = 1.51, 95%CI: 1.07 – 2.14; p = 0.02). No statistical significance was observed in CR (OR = 2.20, 95%CI: 0.68 – 7.08, p = 0.19) or PR (OR = 1.41, 95%CI: 0.99 – 2.01, p = 0.06). No statistical significance was observed in anemia (OR = 0.87, 95%CI: 0.21 –3.59, p = 0.85), neutropenia (OR = 1.21, 95%CI: 1.51 – 2.87, p = 0.56), thrombocytopenia (OR = 2.35, 95%CI: 0.52 – 10.75, p = 0.42) or nausea/vomiting (OR = 1.41, 95%CI: 0.70 – 2.87, p = 0.33) in prolonged, low dose infusion of gemcitabine compared to standard dose rate infusion. Conclusions: Prolonged, low dose infusion of gemcitabine showed better efficacy than standard dose rate infusion, without significant increase of side-effect rate.
Abstract P347: Lower Optimism is Associated With Heart Failure Readmissions
Authors: Gretchen L Wells, Mary Fisher, Gaixin Du
Journal: Circulation (2019)

Introduction: Heart failure is one of the most common reasons for hospitalizations in the U.S. and within 30 days of discharge, nearly one in four patients have been readmitted. While optimism is associated with favorable cardiovascular outcomes, including incident coronary heart disease events and readmission post coronary artery bypass surgery, no data exist for the role of optimism in heart failure patients. Hypothesis: We assessed the hypothesis that optimism is associated with 30 day hospital readmission in heart failure patients. Methods: Optimism is measured using the revised Life Orientation Test (LOT-R) a brief, well-validated scale of optimism. This test was administered by convenience sampling to hospitalized adult (&gt;18 years) heart failure patients to determine if low LOT-R scores (less optimistic) were associated with 30 day hospital readmission. Results: Patients in the lower quartile of optimism scores (or pessimistic) had a higher rate of all cause 30 day readmission compared with those in the highest quartile (p=0.0290). Conclusion: In a single center series of hospitalized heart failure patients, those patients with low optimism scores had a significantly higher all-cause 30 day readmission rate compared with those in the highest quartile of optimism scores. Optimism is trait-like yet may be modifiable, thus presenting an opportunity for intervention in heart failure.
Abstract 16548: Risk of Left Atrial Scarring in Patients With Obstructive Sleep Apnea
Authors: Sanghamitra Mohanty, Prasant Mohanty, Chintan Trivedi, Carola Gianni, John D Burkhardt, Javier Sanchez, Patrick Hranitzky, G J Gallinghouse, Amin Al-Ahmad, Rodney Horton, Domenico G Della Rocca, Luigi Di Biase, Andrea Natale
Journal: Circulation (2017)

Introduction: It is known from animal models that obstructive sleep apnea (OSA) promotes myocardial inflammation which may lead to atrial fibrosis. Patients with OSA show high prevalence of atrial ...
Clinical outcomes of muscle-invasive bladder cancer patients with hydronephrosis treated with tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy.
Authors: Toshiki Kijima, Shohei Fukuda, Hiroshi Fukushima, Shingo Moriyama, Sho Uehara, Yosuke Yasuda, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii
Journal: Journal of Clinical Oncology (2019)

430 Background: Trimodality bladder sparing therapy has become an accepted treatment for selected patients with muscle-invasive bladder cancer (MIBC). As the presence of hydronephrosis may reduce complete response rate and survival in trimodality therapy, some investigators deem hydronephrosis as a contraindication for bladder sparing. We have developed a tetra-modality bladder sparing therapy (TeMT) consisting of maximal transurethral resection (TUR), induction chemoradiotherapy (CRT), and partial cystectomy (PC) (Koga et al, BJU Int 2012). TeMT which enables surgical consolidation of the original MIBC site, including uretero-vesical anastomosis if necessary, may provide more chance of bladder sparing for patients with hydronephrosis. Methods: In total, 151 patients with cT2-3N0M0 MIBC (median age 69 years, female/male = 33/118, cT2/3 = 100/51) entered tetra-modality bladder-sparing protocol. After maximal TUR and CRT (40 Gy + cisplatin), response was evaluated via cytology, imaging, and tumor-site rebiopsy. Consolidative PC was performed in complete responders, while radical cystectomy was recommended for others. Extension of ipsilateral intrapelvic ureter in pretreatment computed tomography was graded following the Society for Fetal Urology grading system, then patients with grade 2-3 were classified as with hydronephrosis. Response rate to CRT, MIBC recurrence-free survival, and cancer-specific survival (CSS) were compared between patients with or without hydronephrosis. Results: Hydronephrosis was found in 19 patients (14%), and was associated with lower response rate to CRT (42% in hydronephrosis vs 77% in normal, p = 0.03). On an intent-to-treat basis, patients with hydronephrosis (n = 19) had lower 5-yr CSS than those without it (n = 132) (62% vs 85%, p &lt; 0.01). Among the 106 patients who underwent PC as per protocol, patients with (n = 9) and without hydronephrosis (n = 97) had comparable 5-yr MIBC recurrence-free survival (100% vs 97%, p = 0.11) and CSS (100% vs 93%, p = 0.46). Conclusions: Patients with hydronephrosis should not necessarily be excluded from tetra-modality bladder sparing therapy.